Abstract: The present invention relates to: a method for preparing a non-oxidized carbon nanotube dispersion through mechanical impregnation so as to apply carbon nanotubes having a hydrophobic surface and a bundle shape as a high-performance conductive material of a negative electrode or a positive electrode for a secondary battery through solvent dispersion without acid treatment; and a non-oxidized carbon nanotube dispersion for a conductive material of a secondary battery, prepared by the method.

Abstract: A composition includes mixed bacterial strains of Bacillus sp. pfbarrier 01 (KCTC 14628BP), Lactobacillus pentosus pfbio035 (KCTC 14684BP) and Lactobacillus sakei subsp. sakei pfbio005 (KCTC 14130BP), a culture solution thereof, or a compound extract thereof as an active ingredient to offer beneficial activities in improving skin wrinkles, moisturizing skin, strengthening skin barriers, and promoting regeneration of wounded skin. The composition poses non-cytotoxicity and high beneficial effects to improve skin wrinkles, moisturize skin, strengthen skin barriers, and help regeneration of wounded skin, which makes it highly applicable to the fields of foods and cosmetics. Besides, the composition is not only very safe for the human body but also has high stability.

Abstract: The present disclosure relates to a reduced graphene oxide for a secondary battery, a method for preparing the same, an electrode using the same, and a secondary battery using the same. Specifically, the reduced graphene oxide is a powdery two-dimensional crystalline reduced graphene oxide satisfying Relational Expressions 1 to 3 shown below. [Relationship 1] 1?TQ?5 [relational expression 2] 100?EQ?1,000 [Relationship 3]1?BETQ?100. In Relational Expression 1, TQ represents the thickness (nm) of the reduced graphene oxide. In Relational Expression 2, EQ represents the electrical conductivity (S/cm) of the reduced graphene oxide. In Relational Expression 3, BETQ represents the specific surface area (m2/g) of the reduced graphene oxide.

Abstract: The present invention relates to a reduced-graphene-oxide/silicon-metal-particle composite, a method of manufacturing the composite and an electrode for a secondary battery including the composite. The method of manufacturing the reduced-graphene-oxide/silicon-metal-particle composite includes preparing a reduced-graphene-oxide dispersion solution by reducing graphene oxide formed through cation-pi interaction, preparing a reduced-graphene-oxide/silicon-metal-particle dispersion solution by mixing the reduced-graphene-oxide dispersion solution with silicon metal particles, and manufacturing a composite powder having a core-shell structure by drying the reduced-graphene-oxide/silicon-metal-particle dispersion solution. Thereby, reduced graphene oxide can be formed using the graphene oxide dispersion solution having few defects and high purity obtained through cation-pi interaction, and dried to afford a composite powder having a core-shell structure, which is applicable to an electrode for a secondary battery.

Abstract: A method of fabricating the organic-inorganic hybrid coating layer includes: preparing a gel mixture including an organic precursor and colloidal silica particles; preparing a first mixed solution by heating the gel mixture; preparing a second mixed solution by adding quantum dots to the first mixed solution; and coating the second mixed solution on a substrate and irradiating light thereon to form a polymer matrix in which the organic precursor and the colloidal silica particles are crosslinked, and preparing a coating layer in which the quantum dots are dispersed in the polymer matrix, wherein the organic precursor may include at least one of dipentaerythritol pentaacrylate (DPPA) or dipentaerythritol hexaacrylate (DPHA).

Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: Disclosed is a method of preparing a pH-sensitive controlled-release emulsion hydrogel using chitosan and pectin. More particularly, disclosed is a method of preparing a pH-sensitive controlled-release emulsion hydrogel that is capable of entrapping various substances to be encapsulated and is stable in gastrointestinal conditions, but upon exposure to neutral pH after passing through the stomach, releases the entrapped emulsion in response to the pH.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: A method of fabricating the organic-inorganic hybrid coating layer includes: preparing a gel mixture including an organic precursor and colloidal silica particles; preparing a first mixed solution by heating the gel mixture; preparing a second mixed solution by adding quantum dots to the first mixed solution; and coating the second mixed solution on a substrate and irradiating light thereon to form a polymer matrix in which the organic precursor and the colloidal silica particles are crosslinked, and preparing a coating layer in which the quantum dots are dispersed in the polymer matrix, wherein the organic precursor may include at least one of dipentaerythritol pentaacrylate (DPPA) or dipentaerythritol hexaacrylate (DPHA).

Abstract: The present disclosure provides a quantum dot thin film that is formed by cross-linking ligands of quantum dots with a photo cross-linker containing two or more azide groups. According to still another aspect of the present disclosure, a method for forming a quantum dot pattern includes: forming a quantum dot layer on a substrate by coating the substrate with a solution including quantum dots and a photo cross-linker containing two or more azide groups; placing a mask having a pattern on the quantum dot layer and performing UV exposure on the quantum dot layer; and forming a quantum dot pattern by removing a non-exposed region of the quantum dot layer.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: A secondary battery using a vanadium oxide as a positive electrode active material is provided. The secondary battery is prevented from degradation of capacity by preventing dissolution of vanadium. The vanadium oxide includes secondary particles formed by assemblage of primary particles.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: The present invention relates to a reduced-graphene-oxide/silicon-metal-particle composite, a method of manufacturing the composite and an electrode for a secondary battery including the composite. The method of manufacturing the reduced-graphene-oxide/silicon-metal-particle composite includes preparing a reduced-graphene-oxide dispersion solution by reducing graphene oxide formed through cation-pi interaction, preparing a reduced-graphene-oxide/silicon-metal-particle dispersion solution by mixing the reduced-graphene-oxide dispersion solution with silicon metal particles, and manufacturing a composite powder having a core-shell structure by drying the reduced-graphene-oxide/silicon-metal-particle dispersion solution. Thereby, reduced graphene oxide can be formed using the graphene oxide dispersion solution having few defects and high purity obtained through cation-pi interaction, and dried to afford a composite powder having a core-shell structure, which is applicable to an electrode for a secondary battery.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: Disclosed are a method of preparing liposomes using a mixed solvent of ethyl acetate and n-hexane for dissolving phospholipids, and a method of preparing a liposome frozen powder by putting a container including liposomes in a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, which methods are useful in food industry for no use of toxic chloroform. Disclosed also is adding the produced container including liposomes to a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, thus advantageously preventing deterioration in stability of liposome particles, as well as being almost completely returned to the original state.

Abstract: The present invention relates to a positive electrode for a secondary battery in which a maximum diameter of internal pores is controlled to be less than 1 ?m, a method of preparing the same, and a secondary battery including the positive electrode.

Abstract: The present disclosure provides a quantum dot thin film that is formed by cross-linking ligands of quantum dots with a photo cross-linker containing two or more azide groups. According to still another aspect of the present disclosure, a method for forming a quantum dot pattern includes: forming a quantum dot layer on a substrate by coating the substrate with a solution including quantum dots and a photo cross-linker containing two or more azide groups; placing a mask having a pattern on the quantum dot layer and performing UV exposure on the quantum dot layer; and forming a quantum dot pattern by removing a non-exposed region of the quantum dot layer.

Abstract: Provided is an electrode, comprising: an electrode current collector, a metal nanowire formed on a surface of the electrode current collector, and a conductive layer surrounding the outside of the metal nanowire, wherein a gap is formed between the metal nanowire and the conductive layer, so that the metal nanowire and the conductive layer are spaced apart from each other without direct contact between them.